In an in vitro AD model, the overexpression of ACE2 was demonstrated to mitigate pathological angiogenesis and diminish BBB damage by inhibiting the activity of the NF-κB/VEGF/VEGFR2 pathway and restoring the expression of ZO-1 and claudin-5 [199]. This evidence concerns the gene ACE2 and Alzheimer disease.